Optimistic Outlook for Ascendis Pharma: Buy Rating Driven by COACH Phase 2 Trial and Yorvipath Launch

Analyst Derek Archila of Wells Fargo maintained a Buy rating on Ascendis Pharma (ASND – Research Report), retaining the price target of $289.00.

Derek Archila has given his Buy rating due to a combination of factors influencing Ascendis Pharma’s potential growth. A significant aspect is the upcoming COACH Phase 2 trial results for achondroplasia, which could offer a modest upside to the company’s shares. The trial investigates the combination of navepegritide and Skytrofa, with promising endpoints such as annualized growth velocity and safety.
Additionally, the launch of Yorvipath for Hypoparathyroidism (HypoPTH) is expected to be a major driver for the company’s stock, potentially pushing it above $200 by the end of 2025. While there is some skepticism regarding the long-term effects of growth hormone treatment in achondroplasia, the potential for additive effects with CNP treatment could enhance growth outcomes. These elements contribute to Archila’s optimistic outlook on Ascendis Pharma’s stock performance.

In another report released on May 19, Morgan Stanley also maintained a Buy rating on the stock with a $250.00 price target.